Trial Profile
A Phase IV, Open-Label Study to Characterize the First-Dose and Multiple-Dose Pharmacokinetics of Raltegravir in the Gastrointestinal Tract of Healthy Male Volunteers.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 17 Nov 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 17 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.